title: Optimizing the role of FDG PET-CT for potentially operable metastatic colorectal cancer.
abstract: Recent treatment advances now allow a realistic chance of cure in selected patients with metastatic colorectal carcinoma (CRC). Accurate pre-treatment staging is crucial to ensure appropriate management by identification of patients with more advanced disease who will not benefit from surgery. (18)Fluorine 2-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography (PET-CT) has a firmly established role in staging, restaging, and recurrence detection of a range of tumors. This article will review the role of PET-CT in patients with CRC with a particular emphasis on optimizing the technique in patients with potentially operable metastatic disease.
authors.affiliation: Department of Clinical Radiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
authors.forename: A D
authors.initials: AD
authors.lastname: Culverwell
authors.forename: F U
authors.initials: FU
authors.lastname: Chowdhury
authors.forename: A F
authors.initials: AF
authors.lastname: Scarsbrook
mesh_terms: D002272:Carcinoembryonic Antigen / Q000097:blood; D023881:Colonography, Computed Tomographic; D015179:Colorectal Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology* / Q000601:surgery; D003362:Cost-Benefit Analysis; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D064847:Multimodal Imaging / Q000191:economics; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed
chemical_list: D002272:Carcinoembryonic Antigen; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18